323 related articles for article (PubMed ID: 34664244)
1. Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer.
Iesato A; Nucera C
Adv Exp Med Biol; 2021; 1329():253-269. PubMed ID: 34664244
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract][Full Text] [Related]
3. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
4. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
5. Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors.
Zhu J; Yang W; Ma J; He H; Liu Z; Zhu X; He X; He J; Chen Z; Jin X; Wang X; He K; Wei W; Hu J
EMBO J; 2024 Apr; 43(8):1519-1544. PubMed ID: 38528180
[TBL] [Abstract][Full Text] [Related]
6. Pericytes in Breast Cancer.
Kim J
Adv Exp Med Biol; 2019; 1147():93-107. PubMed ID: 31147873
[TBL] [Abstract][Full Text] [Related]
7. Targeting pericytes for angiogenic therapies.
Kelly-Goss MR; Sweat RS; Stapor PC; Peirce SM; Murfee WL
Microcirculation; 2014 May; 21(4):345-57. PubMed ID: 24267154
[TBL] [Abstract][Full Text] [Related]
8. TGF-β signaling promotes tumor vasculature by enhancing the pericyte-endothelium association.
Zonneville J; Safina A; Truskinovsky AM; Arteaga CL; Bakin AV
BMC Cancer; 2018 Jun; 18(1):670. PubMed ID: 29921235
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a 3D model of tumor-driven angiogenesis to study the effects of anti-angiogenic drugs on pericyte recruitment.
Qiu Y; Wang N; Guo T; Liu S; Tang X; Zhong Z; Chen Q; Wu H; Li X; Wang J; Zhang S; Ou Y; Wang B; Ma K; Gu W; Cao J; Chen H; Duan Y
Biomater Sci; 2021 Sep; 9(18):6064-6085. PubMed ID: 34136892
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
11. Pericytes in Metastasis.
Pieterse Z; Sinha D; Kaur P
Adv Exp Med Biol; 2019; 1147():125-135. PubMed ID: 31147875
[TBL] [Abstract][Full Text] [Related]
12. Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy.
Chen Z; Xu XH; Hu J
Neoplasma; 2016; 63(2):173-82. PubMed ID: 26774138
[TBL] [Abstract][Full Text] [Related]
13. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
14. Specific targeting of PDGFRβ in the stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression.
Tsioumpekou M; Cunha SI; Ma H; Åhgren A; Cedervall J; Olsson AK; Heldin CH; Lennartsson J
Theranostics; 2020; 10(3):1122-1135. PubMed ID: 31938055
[TBL] [Abstract][Full Text] [Related]
15. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C; Thaker PH; Lin YG; Spannuth W; Landen CN; Merritt WM; Jennings NB; Langley RR; Gershenson DM; Yancopoulos GD; Ellis LM; Jaffe RB; Coleman RL; Sood AK
Am J Obstet Gynecol; 2008 Apr; 198(4):477.e1-9; discussion 477.e9-10. PubMed ID: 18395047
[TBL] [Abstract][Full Text] [Related]
16. Pericyte-targeting drug delivery and tissue engineering.
Kang E; Shin JW
Int J Nanomedicine; 2016; 11():2397-406. PubMed ID: 27313454
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological PDGFRβ inhibitors imatinib and sunitinib cause human brain pericyte death in vitro.
King NE; Courtney JM; Brown LS; Foster CG; Cashion JM; Attrill E; Premilovac D; Howells DW; Sutherland BA
Toxicol Appl Pharmacol; 2022 Jun; 444():116025. PubMed ID: 35443205
[TBL] [Abstract][Full Text] [Related]
18. Pericytes: a double-edged sword in cancer therapy.
Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
[TBL] [Abstract][Full Text] [Related]
19. Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions.
Sattiraju A; Mintz A
Adv Exp Med Biol; 2019; 1147():65-91. PubMed ID: 31147872
[TBL] [Abstract][Full Text] [Related]
20. Pericytes in the tumor microenvironment.
Jiang Z; Zhou J; Li L; Liao S; He J; Zhou S; Zhou Y
Cancer Lett; 2023 Mar; 556():216074. PubMed ID: 36682706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
